Biology of Blood and Marrow Transplantation
Volume 14, Issue 9, Supplement , Pages 2-7 , September 2008

The National Marrow Donor Program 20 Years of Unrelated Donor Hematopoietic Cell Transplantation

  • Karen K. Ballen

      Affiliations

    • Massachusetts General Hospital, Boston, Massachusetts
    • Corresponding Author InformationCorrespondence and reprint requests: Karen Ballen, MD, Division of Hematology/Oncology, Massachusetts General Hospital, Zero Emerson, Suite 118, Boston, MA 02114.
    • ,
  • Roberta J. King

      Affiliations

    • National Marrow Donor Program, Minneapolis, Minnesota
    • ,
  • Pintip Chitphakdithai

      Affiliations

    • National Marrow Donor Program, Minneapolis, Minnesota
    • ,
  • Charles D. Bolan Jr.

      Affiliations

    • Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Rockville, Maryland
    • ,
  • Edward Agura

      Affiliations

    • Baylor University Medical Center, Houston, Texas
    • ,
  • Robert J. Hartzman

      Affiliations

    • C.W. Bill Young/Department of Defense Marrow Donor Program, Naval Medical Research Center, Rockville, Maryland
    • ,
  • Nancy A. Kernan

      Affiliations

    • Memorial Sloan Kettering Cancer Center, New York, New York

Received 23 May 2008 ,Accepted 27 May 2008.

References 

  1. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoeitic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390–3400
  2. Daly A, McAfee S, Dey B, et al. Nonmyeloablative bone marrow transplantation: infectious complications in 65 recipients of HLA-identical and mismatched transplants. Biol Blood Marrow Transplant. 2003;9:373–382
  3. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481–3485
  4. Section 13. Leukemia. In:  Ries LAG,  Eisner MP,  Kosary CL,  Hankey BF,  Miller BA,  Clegg L,  Mariotto A,  Feuer EJ,  Edwards BK editor. SEER [Surveillance Epidemiology and End Results] Cancer Statistics Review, 1975-2001. Bethesda, MD: National Cancer Institute; 2004;
  5. Ballen KK, King R, Carston M, et al. Outcome of unrelated transplants in patients with multiple myeloma. Bone Marrow Transplant. 2005;35:675–681
  6. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral blood stem-cell transplantation. N Engl J Med. 2000;343:750–758
  7. Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. N Engl J Med. 1991;324:1297–1304
  8. Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: update of the GITMO/EBMT study on 100 patients. Blood. 2000;95:1931–1934
  9. Deeg HJ, Seidel K, Casper J, et al. Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. Biol Blood Marrow Transplant. 1999;5:243–252
  10. Baker KS, Hassebroek A, Ballen K, et al. Impact of ethnicity and socioeconomic status on outcome of unrelated donor (URD) hematopoietic stem cell transplantation (HcT). Blood (ASH Annual Meeting Abstracts). 2007;110:3064
  11. Schipper RF, D'Amaro J, Bakker JT, Bakker J, van Rood JJ, Oudshoorn M. HLA gene and haplotype frequencies in bone marrow donors worldwide registries. Hum Immunol. 1997;52:54–71
  12. Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematologic diseases. Blood. 2003;101:1620–1629
  13. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756–763
  14. Dey BR, McAfee S, Sackstein R, et al. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation. Biol Blood Marrow Transplant. 2001;7:604–612
  15. Giralt S, Logan B, Rizzo D, et al. Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the National Marrow Donor Program. Biol Blood Marrow Transplant. 2007;13:844–852
  16. Mori M, Graves M, Milford EL, Beatty PG. Computer program to predict likelihood of finding an HLA-matched donor: methodology, validation, and application. Biol Blood Marrow Transplant. 1996;2:134–144

 STATEMENT OF CONFLICT OF INTEREST: See Acknowledgments on page 7.

PII: S1083-8791(08)00230-9

doi: 10.1016/j.bbmt.2008.05.017

Biology of Blood and Marrow Transplantation
Volume 14, Issue 9, Supplement , Pages 2-7 , September 2008

Article Tools

* Image Usage & Resolution